R&D

Pipeline

HOME  >  R&D  >  Pipeline

The problem and market of IBD

The problem
문제점
The market
시장현황
The mechanism of other developed agents
1. Biologics – Anti TNF-α blocker
2. Aminosalicylic acid
3. Steroid

NIBEC solution for IBD

  • Derivatives of NIPEP-CARE by amino acid substitution
  • Dual targeting for 1) wound healing and 2) anti-inflammatory effect
  • Defined target molecule (first in class) : 3 DIFFERENT IBD ASSETS DEVELOPED
  • Best for immune reaction masking effect and simultaneous mucosal healing
  • Recovery from inflammation invasion reflected by histology
  • Current status: Preclinical efficacy, GLP TOX COMPLETED (1 asset, ready for phase 1) MOA and colon specific delivery formulation design
  • Administration route: Injection, Oral colon targeting formulation

NIPEP-CARE for IBD

NIPEP-CARE improves inflammatory disease activity driven by TNBS animal model :
Treatment by the sc injection of the peptide

Histology of NIPEP-CARE in IBD models

NIPEP-CARE improves inflammatory disease activity driven by DSS induced IBD model :
Treatment by the sc injection of the peptide

NIPEP-CARE. Non-clinical toxicity test

Non-clinical toxicity test

Safety pharmacology
Test Administration route Dose (mg/kg) Result
hERG assay in vitro 300, 1000μM IC50> 1000μM
Mouse neurological effect (IRWIN test) SC injection 0, 250, 500, 1000 NOAEL=1000mg/kg
Monkey cardioheamodynamic effect (Telemetry) SC injection NOAEL=1000mg/kg
mouse pulmonary effect (Plethysmography) SC injection NOAEL=1000mg/kg

The effect of peptide ORAL administration on IBD mouse induced by 5% DSS : 7 DAY results

The effect of peptide ORAL administration on IBD mouse induced by 5% DSS : 7 DAY results

Oral formulation for colon delivery : All formulation is available at NIBEC GMP facility